email.
Moderna is studying a new version of its COVID-19 vaccine that could be kept refrigerated for up to three months, according to a statement released Thursday. Currently, the vaccine can be stored at refrigerator temperatures for one month after being thawed from its frozen storage temperature, which requires ultra cold-chain equipment that is not widely available globally. If authorized, the refrigerator-stable vaccine could increase the number of locations able to vaccinate using Moderna’s shot. The company also announced plans to invest in manufacturing facilities in Switzerland, Spain, and the United States, which would boost its capacity to produce up to 3 billion doses of the mRNA-based vaccine in 2022.
Au bord du fleuve Congo : la maladie du sommeil en voie d éradication
franceculture.fr - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from franceculture.fr Daily Mail and Mail on Sunday newspapers.
L Afrique face au Covid-19 : la peur du scénario indien
lemonde.fr - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lemonde.fr Daily Mail and Mail on Sunday newspapers.
Largest clinical trial in Africa for people with mild COVID-19 to test new treatment
eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
2021-04-28 14:00:00
Enhancing mother’s gifts: Up and coming vaccines for pregnant women to protect their newborns from infections World Immunisation Week 2021
To mark World Immunisation Week 2021 from 24 to 30 April, the London School of Hygiene & Tropical Medicine (LSHTM) Vaccine Centre is hosting a series of webinars. The theme this year is ‘Vaccines Bring Us Closer’. Each day of the week we focus on an important area of vaccine research, science and debate bringing together experts in the field. We end the week with the Vaccine Centre Annual Lecture on 30 April.
In this event, we focus on vaccines that are currently undergoing clinical trials and are aiming to protect newborn babies from RSV and Group B streptococcus. Professor Kirsty Le Doare will discuss Group B Streptococcus (GBS) Vaccines, an update and Dr Fiona Culley will explore Maternal vaccines for Respiratory Syncytial Virus (RSV) .